US FDA issues Complete Response Letter rejecting Allergan’s Biologics License Application for abicipar pegol for neovascular age-related macular degeneration

Rejection is based on unfavourable risk-benefit ratio relating to rate of intraocular inflammation observed following administration of this new vascular endothelial growth factor A inhibitor.It was filed for approval in EU in June 2019.


Biospace Inc.